News Releases

Media Coverage


Title Subtitle Publisher
Success Secrets Q&A for BioVentures Comprehensive Entrepreneurs’ Guide from Anxieties to Investment Questions! Yodosha Corporation

The Fiscal Year of 2020

Publication date Media Title/Summary
Dec 02, 2020 WEB Nikkei Biotech Online Oji HD to form capital and business alliance with ReqMed Oji Pharma, a subsidiary of Oji HD, and ReqMed established an R&D partnership.
Dec 02, 2020 WEB Nikkei Business Why Oji HD formed a capital and business alliance with a biotech venture?
Nov 27, 2020 WEB Nihon Keizai Shimbun Oji Holdings (HD) announced on November 27th that it will form a capital and business alliance with biotech venture ReqMed

The Fiscal Year of 2015

Publication date Media Title/Summary
Sep 8, 2014 Newspaper Nikkan Yakugyo Discussed on cost accounting and mentioned “substantial post-approval assistance” and “Innovative drug is not necessarily a bio drug with high production cost” at the RS Society

The Fiscal Year of 2013

Publication date Media Title/Summary
Feb 01, 2014 Journal Iyaku Keizai, February 1, 2014 p.48~p.49 interview
Requesting reasonable NHI prices, the government should also be prepared
Dec 01, 2013 WEB Nikkei Biotech Online MHLW convenes the First Committee of the Pharmaceutical Affairs Council approves the approval of ReqMed’s Cystadan® bulk powder On November 29, 2013, the Ministry of Health, Labor and Welfare (MHLW) held the First Committee of the Pharmaceutical Affairs and Food Sanitation Council to deliberate and report on Cystadan® bulk powder, an application filed by ReqMed, and other drugs, and approved them all.
Aug 28, 2013 Newspaper Nikkan Yakugyo MHLW Notifies Generic Names of Drug Candidates The Ministry of Health, Labour and Welfare’s Pharmaceutical and Food Safety Bureau notified prefectural governments of betaine as one of 11 drug candidate compounds with a generic name (JAN) in Japan on August 23.
Jun 01, 2013 Journal NEW CURRENT June 1, 2013 (Vol. 24, No. 12) p.49 – p.50 Patent Information Digest of Drug and Compound Patents “Pentosan Polysulfate Pentosan polysulfate shows promise as a fundamental treatment in clinical studies of HTLV-1-related myelopathy
Apr 05, 2013 Newspaper Nikkei Sangyo Shimbun Congenital disease drug ReqMed filed for uremia, domestic production version. Bio-venture company ReqMed (Machida City, Tokyo) announced that it has applied for domestic manufacturing and marketing approval of betaine anhydrous (generic name) for the indication of the congenital disease “homocystinuria”.
Apr 04, 2013 WEB Nikkei Biotech Online ReqMed filed for approval of a new drug for homocystinuria, a rare disease with about 100 patients in Japan. On March 29, 2013, ReqMed (Machida City, Tokyo, President Tadashi Matsumoto) applied for manufacturing and marketing approval of Cystadan® bulk powder (betaine anhydride), a drug for homocystinuria.